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Using an earlier model of the favoured orientation of binding functions of angiotensin converting enzyme 
(ACE) inhibitors, it has been possible to postulate a new, 7,6_bicyciic system, based on 
hexahydropyrida~ne, which might be expected to have high potency. Some members of this system which 
have been synthesised have been shown to be very active ACE inhibitors, in vitro and in vivo. 
Angiotensin-converting e zyme Inhibitor Design Antihypertensive 
1, INTRODUCTION 
Recent evidence relating to the compounds cap- 
topril [If, enalapril (MK 421) [2] and others [3] has 
confirmed the potential of inhibitors of angioten- 
sin converting enzyme (ACE, EC 3.4.15.1) as 
agents for the treatment of hypertension [4,5] and 
congestive heart failure in man [6,7]. This has pro- 
mpted considerable interest in the search for alter- 
native ACE inhibitors which could have enhanced 
value in human therapy. In an earlier publication 
[8] we outlined a basis for designing compounds 
related to captopril but incorporating a bicyclic 
feature as an alternative to the pseudo- 
alanylproline unit. This provided an indication of 
the spatial requirements of the 3 functional groups 
of captopril (the C-terminal carboxyl, amide car- 
bony1 and thiol) essential for good binding to the 
ACE active centre. In a continuation of that study, 
we have sought to replace the thiol by alternative 
binding functions suggested by evidence of 
substrate-ACE interactions [9], and to optimise 
the orientations of the C-terminal carboxyl and 
amide carbonyl for binding to the enzyme. This 
had led to the identification of a new family of 
very potent thiol-free ACE inhibitors with 
favourable characteristics for in vivo applications. 
display processor interfaced to a VAX1 l/750 com- 
puter and a Calcomp 81 plotter. NMR spectra were 
determined on Varian XL-100 and Bruker 
WM-300 spectrometers. X-ray diffraction data 
were provided by Dr J.J. Daly (F. Hoffmann-La 
Roche, Basle). Full descriptions of the methods 
used in chemistry, biochemistry and pharmacology 
will follow in later publications. 
Rabbit lung and hog kidney enzymes were 
prepared from acetone powders [lo]. Human en- 
zyme was from plasma. The enzyme activities were 
determined [lo,1 l] by measuring the release of hip- 
puric acid from the substrate Hip-His-Leu. Assays 
were conducted with 2 mM substrate, 100 mM 
phosphate buffer (pH 8.3) containing 300 mM 
NaCl. Reactions initiated by addition of enzyme to 
a mixture of substrate and inhibitor at 37°C were 
allowed to proceed for 25 min (rabbit lung and hog 
kidney enzymes) or 60 min (human plasma). In the 
case of the diluted (40-fold) rabbit lung enzyme 
assay the incubation time was extended to 24 h. 
A modified radiometric rabbit lung ACE/Hip- 
His-Leu assay [IO, 121 was used for measurement 
of in vivo plasma ACE activity. 
2. EXPERIMENTAL 
Computer graphics utilised a Megatek 7000 
The ability of selected compounds to block 
ACE-mediated release of histidylleu~ine from 
angiotensin I was examined. Assays were con- 
ducted in 100 mM phosphate buffer (pH 7.5) con- 
taining 30 mM NaCl, the substrate concentration 
being 0.4 mM. Reactions, initiated by addition of 
substrate to a pre-incubated mixture of enzyme 
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and inhibitor, were allowed to proceed at 37°C for 
30 min. Appearance of the dipeptide product was 
monitored fluorimetrically [ 131. 
Selected compounds were also examined quan- 
titatively for their ability to inhibit angiotensin I- 
induced contractions of the guinea pig ileum in 
vitro. In vivo ACE inhibitory potency was assessed 
in the anaesthetised rat from the decrease in 
angiotensin (1 pg/kg) pressor response at 15 min 
after intravenous administration of inhibitor. 
Systolic arterial pressure was recorded from a 
carotid arterial cannula connected to a pressure 
transducer. Data were controlled by relating them 
to the pre- and post-dose angiotensin II (1 pg/kg) 
pressor responses [14]. Potency and duration of 
action were also assessed for plasma ACE inhibi- 
tion following oral administration of selected 
inhibitors. 
The extent of oral absorption was determined 
from the relative urinary recovery of radioactivity 
after oral and intravenous doses of 14C-labelled 
compound. 
3. RESULTS AND DISCUSSION 
The scaled graphical representation of captopril 
in 3 dimensions in comparison with our earlier 
bicyclic analogues [8,15] suggested that the 
J7 
Salt Bridge 
Fig. 1. The computer-drawn structures of alanylproline (dotted) line and the 7,6-bicyclic compound I (diacid form) (full 
line), overlaid in space and placed in the ACE active site derived previously, with the 3 binding interactions highlighted. 
The basic structures are based on X-ray diffraction data on closely related compounds. For clarity, the two structures 
are offset slightly. 
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6,6-bicyclic system incorporating a hexa- 
hydropyridazine nucleus might be modified to 
enhance binding to the ACE active centre. In the 
6,6-series the methylene group of the pseudo- 
alanine assumed a position corresponding to the 
high-energy conformation of Ala-Pro in which the 
methyl group almost eclipsed the proline d-carbon. 
We postulated that this strain could be avoided 
and a more favoured position of this methylene 
would be produced in a compound with the related 
7,6-bicyclic system (fig. 1). 
The compounds retaining the favoured S,S- 
configuration for carboxyl and side chain 
substitutents at positions 1,9 were synthesised both 
with and without 6-oxo-functionality by means of 
the procedures indicated in table 3. The conforma- 
tions of the two 7,6-bicyclic systems were indicated 
by NMR spectroscopy and later confirmed by X- 
ray diffraction. Moreover, the graphics showed 
(fig. 1) that this enabled the carboxyl, amide car- 
bony1 and 8-methylene group to simulate the posi- 
tions in space of the corresponding functions in a 
favoured conformation of L,L-Ala-Pro. We 
reasoned that, given this, the binding of such a 
rigid bicyclic system might well give rise to an en- 
tropy gain in comparison with the more flexible 
substrates; this would be reflected in higher poten- 
cy. The C-9 substituent group Ph(CH&CH(C02- 
Et)-NH- for the compound I (Ro 31-2848) was 
chosen, as in other cases [16, 171, as an alternative 
to the thiol in captopril to favour in vivo charac- 
teristics [2], and at the same time to provide for 
good binding to the receptor; this choice can be 
related to the structure of typical ACE cleavage 
products [18]. We found, like others, that the 
substituent R2 attached to the glycine moiety could 
be varied in several cases with little change in 
potency (table 1). 
The in vitro activities of representative 
7,6-bicyclic compounds as ACE inhibitors are 
listed in table 1; these are compared with MK 
421-diacid, SRI-20 and captopril as inhibitors of 
different ACE preparations, using angiotensin-1 
and Hip-His-Leu as substrates. It is evident from 
table 1 that the new 7,6-bicyclic system favours 
high potency in vitro. The results in table 2 
establish that the diacid derivative of compound I 
is an exceptionally potent inhibitor. The diluted 
enzyme assay was undertaken to avoid the 
possibility that the estimate of potency might be 
Table 1 
Inhibition of rabbit lung ACE-induced Hip-His-Leu 
cleavage in vitro 
n x ZOO WI) 
(I) E”t 
Et 
(II) E”t 
H 
Et 
H 
Et 
Et 
Et 
H 
H 
H 
H 
H 
PhCHzCHz* 1 
PhCHzCH2 2 
I%N(CH&* 2 
PhCH2CH2 1 
PhCHzCHz 2 
(CHs)2CHCH2CH2* 2 
p-MeOPhCH2CH2 2 
PhCH2CH2CH2 2 
H 2 
ZNH(CH2k 2 
ZNHCH2* 2 
PhCH2* 2 
ZNH(CHZ)~* 1 
I+N(CH&* 1 
PhCH2CH2CH2* 1 
(CH&CHCH2CH2* 1 
HZ 56 
Hz 1.8 
Hz 5 
0 20 
0 4 
0 12 
0 3 
0 11 
0 560 
0 5 
0 16 
0 26 
H2 30 
HZ 100 
Hz 56 
H2 100 
When R’ = Et, ISO determined after incubation with hog 
liver esterase 
* Mixture of two isomers 
understated ue to a mutual depletion effect; this 
may arise in cases where enzyme concentration and 
ICSO values are comparable [ 191. 
The potent inhibitor II (Ro 31-2201) and the 
related desoxy compound I (Ro 31-2848) have been 
investigated in animal studies. They confirm that I 
is better absorbed (p.o. 80-100%) than II (p.o. 
20-30%) but both have long-acting high potency in 
the rat for inhibition of plasma ACE when ad- 
ministered orally (fig.2), and high potency for an- 
tagonism of the pressor effect of angiotensin I 
when given intravenously as the diacids (fig.3). 
Detailed pharmacological studies with further 
evidence of the anti-hypertensive properties of 
these compounds in animals and in man will be 
reported elsewhere. 
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Table 2 
Comparative biological evaluation of potent ACE inhibitors 
Inhjbitor Structure IGO value (nM) 
Substrate : Hip - His - Leu 
ICSO value (nM) ZCse value ZDs0 value 
Substrate: fnM) (95% Ormol/ka i.v.) 
Rabbit Human Hog Diluted 
angiotensin I limitsj guinea- Y(95% limits)’ 
lung plasma kidney rabbit 
Rabbit lung pig ileum Al/Al 1 pres- 
ACE ACE ACE lung ACE 
ACE ([Enzyme] SOT inhibition 
([Enzyme] ([Enzyme] ([Enzyme] 
= 0.4 nM) 
= 1.5 = 0.5 = 1.5 = 0.04 
nM) nM) nM) nM) 
I 
Diacid 1.8 0.6 3.3 0.08 0.8 10.9 0.06 
(3.1-16.2) (0.03-0.10) 
0 
II 
Diacid 3.8 1.4 8.3 0.21 0.9 14.3 0.08 
(12.6-16.2) (0.06-0.17) 
MK 421 Diacid &‘A”?- 3.3 1.5 6.0 0.37 1.2 (,4E;29) ~otX& 
. . 
SRI-20 *Q 9.0 13 34 7.0 360 N.D. N.D. 
0 - 
Cartopril na&NT 7.5 14 13 N.D. N.D. 
(3lE657.9) (0.3%76) 
coon 
0 3 6 
TIME (HI 
Fig. 2. The time course for plasma ACE inhibition in the 
rat after oral II (v’) (1 mglkg) and I (A) (0.25 mg/kg). 
%-’ 
3 30 300 
DOSE (MCWKG 1 
Fig. 3. The intravenous dose-response relationship for 
antagonism of the angiotensin I(A1) pressor effect in 
anaesthetised rats (iv.). Diacids of II (v) and I (A). 
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Table 3 
Preparation of N-carboxyalkyl derivatives of bicyclic dipeptide mimetics 
January 1984 
2N 
H’ 
? 
COOR 
ZN 
Q 
COOR 
IN 
HN 
I3 
COOR 
7 
HN 
3 
COOR 
(AFZPh t A k) (b) cc) X COCI 
COOR 
+ (*I t (PIN hN 
0 I 0 
COOR 
I 
COOR 
t (4 (4 (‘1 [d) 
(PIN H2 
COOR COOR 
(A 
+ 
A 
(4 (4 (‘1 
c 
X COCI 
(k) or (1) 
(A) is CH2 or CHzCH2; (P) is protecting group (usually phthaloyl); R and R’ are appropriately Me, Et, ‘Bu or H (inter- 
changeable by standard procedures); RZ - refer to table 1; X is halide or sulphonate leaving group; Z is benzyloxycar- 
bonyl. The required S,S,Sstereochemistry of the products was achieved by stereoselective synthesis or separation of 
isomers as appropriate. (a) toluene/HzO/NaHCO3, (b) Hz/catalyst, (c) SOCWCHzClz, (d) N2&. HzO/EtOH, (3) 
HBr/HOAc, (f) DMF/KzCOj, (g) NaNg/acetone, (h) PhJP, (i) NHdOH, (j) HgB-THF, (k) R2COC0zR’/NABH$N, 
X NH2 
I I 
(1) R2CHC02R’/CH3CN/EtsN, (m) R2CHC02R’/DMF/EtsN 
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